- 作者: Grace Wakabayashi, Yu-Ching Lee, Frank Luh, Chun-Nan Kuo, Wei-Chao Chang and Yun Yen
- 作者服務機構: 1. Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan, 110 2. Center for Cancer Transnational Research, Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan, 110 3. Sino-American Cancer Foundation, 668 Arrow Grand Circle, Suite 101, Covina, California, 91722, USA 4. Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University; Department of Pharmacy, Integrative Therapy Center for Gastroenterologic Cancers, Wan Fang Hospital; Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan, 110 5. PhD Program for Cancer Biology and Drug Discovery, Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan, 110
- 中文摘要:
- 英文摘要:
Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy. - 中文關鍵字:
- 英文關鍵字: Checkpoint inhibitor, Cancer immunotherapy, PD-1 PD-L1 signaling